Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,618.80
(
0.11%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
104.16
(
0.45%
)
Bitcoin
79,606.17
(
0.41%
)
News Focus
News Focus
Post# of 257556
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: caravon post# 225266

Friday, 06/14/2019 7:22:00 PM

Friday, June 14, 2019 7:22:00 PM

Post# of 257556

Some...are trying to compare the ENTA—[RSV]—data with the failed JNJ Ph3 trial.

JNJ’s RSV drug, lumicitabine, did not fail in phase-3; rather, the lumicitabine program was terminated during phase-2 due to an undisclosed safety problem:

#msg-144276889
#msg-147714156

https://www.clinicaltrials.gov/ct2/show/NCT02935673
https://www.clinicaltrials.gov/ct2/show/NCT03333317

In short, there is no read-through from JNJ's RSV program to ENTA's.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today